Application No.: 09/485571

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- [X] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- [ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- [ ] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- [ ] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- [ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- [ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- [ ] 7. Other: _____

Applicant Must Provide:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- [X] An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED
OCT 17 2000
1653
TECH CENTER 1600/2900

RAW SEQUENCE LISTING DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571 TIME: 18:30:34

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

<110> APPLICANT: Calas, et al.
<120> TITLE OF INVENTION: Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
<130> FILE REFERENCE: 19904-009 BREESE-9
<140> CURRENT APPLICATION NUMBER: 09/485,571
<141> CURRENT FILING DATE: 2000-06-09
<150> PRIOR APPLICATION NUMBER: WO 99/07728
<151> PRIOR FILING DATE: 1998-08-06
<160> NUMBER OF SEQ ID NOS: 38
<170> SOFTWARE: PatentIn Ver. 2.0
<210> SEQ ID NO: 1
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized
<400> SEQUENCE: 1
Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val
1 5 10 15
Gly Arg
<210> SEQ ID NO: 2
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized
<400> SEQUENCE: 2
Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Ile Cys Val
1 5 10 15
<210> SEQ ID NO: 3
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized
<400> SEQUENCE: 3
Arg Gly Gly Gly Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val
1 5 10 15
Gly Arg
<210> SEQ ID NO: 4
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

ENTERED

RAW SEQUENCE LISTING DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571 TIME: 18:30:34

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized

<400> SEQUENCE: 4

Arg Gly Gly Arg Leu Cys Tyr Cys Arg Gly Trp Ile Cys Phe Cys Val
1 5 10 15

Gly. Arg

<210> SEQ ID NO: 5
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized

<400> SEQUENCE: 5

Arg Gly Gly Arg Leu Cys Tyr Cys Arg Pro Arg Phe Cys Val Cys Val
1 5 10 15

Gly Arg

<210> SEQ ID NO: 6
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized

<400> SEQUENCE: 6

Arg Arg Trp Cys Phe Arg Val Cys Tyr Arg Gly Phe Cys Tyr Arg Lys
1 5 10 15

Cys Arg

<210> SEQ ID NO: 7
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized

<400> SEQUENCE: 7

Arg Arg Trp Cys Phe Arg Val Cys Tyr Lys Gly Phe Cys Tyr Arg Lys
1 5 10 15

Cys Arg

<210> SEQ ID NO: 8
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: chemically synthesized

<400> SEQUENCE: 8

Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Arg Arg Cys
1 5 10 15

RAW SEQUENCE LISTING DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571 TIME: 18:30:34

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

```
     149 Arg
     153 <210> SEQ ID NO: 9
     154 <211> LENGTH: 17
     155 <212> TYPE: PRT
     156 <213> ORGANISM: Artificial Sequence
     158 <220> FEATURE:
     159 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
     160       synthesized
     162 <400> SEQUENCE: 9
     163 Arg Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Arg Lys Cys
     164   1               5                  10                  15
     166 Arg
     170 <210> SEQ ID NO: 10
     171 <211> LENGTH: 17
     172 <212> TYPE: PRT
     173 <213> ORGANISM: Artificial Sequence
     175 <220> FEATURE:
     176 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
     177       synthesized
     179 <400> SEQUENCE: 10
     180 Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Lys Arg Cys
     181   1               5                  10                  15
     183 Arg
     187 <210> SEQ ID NO: 11
     188 <211> LENGTH: 18
     189 <212> TYPE: PRT
     190 <213> ORGANISM: Artificial Sequence
     192 <220> FEATURE:
     193 <221> NAME/KEY: VARIANT
     194 <222> LOCATION: (1)..(18)
     195 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec
     197 <220> FEATURE:
     198 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
     199       synthesized
     201 <400> SEQUENCE: 11
W--> 202 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
     203   1               5                  10                  15
W--> 205 Xaa Xaa
     209 <210> SEQ ID NO: 12
     210 <211> LENGTH: 18
     211 <212> TYPE: PRT
     212 <213> ORGANISM: Artificial Sequence
     214 <220> FEATURE:
     215 <221> NAME/KEY: VARIANT
     216 <222> LOCATION: (1)..(18)
     217 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec
     219 <220> FEATURE:
     220 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
     221       synthesized
```

RAW SEQUENCE LISTING DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571 TIME: 18:30:34

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

223 <400> SEQUENCE: 12
W--> 224 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
225 1 5 10 15
W--> 227 Xaa Xaa
231 <210> SEQ ID NO: 13
232 <211> LENGTH: 18
233 <212> TYPE: PRT
234 <213> ORGANISM: Artificial Sequence
236 <220> FEATURE:
237 <221> NAME/KEY: VARIANT
238 <222> LOCATION: (1)..(18)
239 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec
241 <220> FEATURE:
242 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
243 synthesized
245 <400> SEQUENCE: 13
W--> 246 Arg Xaa Xaa Arg Xaa Xaa Xaa Xaa Arg Arg Arg Xaa Xaa Xaa Xaa Xaa
247 1 5 10 15
W--> 249 Xaa Arg
253 <210> SEQ ID NO: 14
254 <211> LENGTH: 18
255 <212> TYPE: PRT
256 <213> ORGANISM: Artificial Sequence
258 <220> FEATURE:
259 <221> NAME/KEY: VARIANT
260 <222> LOCATION: (1)..(18)
261 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec.
263 <220> FEATURE:
264 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
265 synthesized
267 <400> SEQUENCE: 14
W--> 268 Arg Arg Xaa Xaa Xaa Arg Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Arg Arg
269 1 5 10 15
W--> 271 Xaa Arg
275 <210> SEQ ID NO: 15
276 <211> LENGTH: 18
277 <212> TYPE: PRT
278 <213> ORGANISM: Artificial Sequence
280 <220> FEATURE:
281 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
282 synthesized
284 <400> SEQUENCE: 15
285 Arg Gly Gly Arg Leu Ser Tyr Ser Arg Arg Arg Phe Ser Val Ser Val
286 1 5 10 15
288 Gly Arg
292 <210> SEQ ID NO: 16
W--> 293 <400> SEQUENCE: 16
W--> 294 .000
296 <210> SEQ ID NO: 17

RAW SEQUENCE LISTING DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571 TIME: 18:30:34

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

297 <211> LENGTH: 18
298 <212> TYPE: PRT
299 <213> ORGANISM: Artificial Sequence
301 <220> FEATURE:
302 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
303 synthesized
305 <400> SEQUENCE: 17
306 Arg Gly Val Ser Val Ser Phe Arg Arg Arg Ser Tyr Ser Leu Arg Gly
307 1 5 10 15
309 Gly Arg
313 <210> SEQ ID NO: 18
314 <211> LENGTH: 18
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
320 synthesized
322 <400> SEQUENCE: 18
323 Glu Gly Gly Glu Leu Ser Tyr Ser Glu Glu Glu Phe Ser Val Ser Val
324 1 5 10 15
326 Gly Glu
330 <210> SEQ ID NO: 19
331 <211> LENGTH: 18
332 <212> TYPE: PRT
333 <213> ORGANISM: Artificial Sequence
335 <220> FEATURE:
336 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
337 synthesized
339 <400> SEQUENCE: 19
340 Arg Gly Gly Arg Leu Ala Tyr Arg Leu Leu Arg Phe Ala Ile Arg Val
341 1 5 10 15
343 Gly Arg
347 <210> SEQ ID NO: 20
348 <211> LENGTH: 18
349 <212> TYPE: PRT
350 <213> ORGANISM: Artificial Sequence
352 <220> FEATURE:
353 <221> NAME/KEY: VARIANT
354 <222> LOCATION: (1)..(18)
355 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec.
357 <220> FEATURE:
358 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
359 synthesized
361 <400> SEQUENCE: 20
W--> 362 Xaa Gly Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
363 1 5 10 15
W--> 365 Xaa Gly
369 <210> SEQ ID NO: 21
370 <211> LENGTH: 18

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571 TIME: 18:30:35

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:202 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:205 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:224 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:227 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:246 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:249 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:268 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:293 M:283 W: Missing Blank Line separator, <400> field identifier
L:294 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (16) SEQUENCE:
L:362 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:365 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:485 M:283 W: Missing Blank Line separator, <400> field identifier
L:486 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (28) SEQUENCE:
L:489 M:283 W: Missing Blank Line separator, <400> field identifier
L:490 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (29) SEQUENCE:
L:524 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:527 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:566 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:585 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:607 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:610 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:629 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:651 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:674 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38